Evicenter
Keytruda (pembrolizumab) in High-risk early-stage triple-negative breast cancer
Manufacturer
Merck Sharp & Dohme LLC
Prescribing information
Keytruda (opens in a new tab)
Questions
28
Last updated

All questions

Clinical trials: Keytruda (pembrolizumab) in high-risk early-stage triple-negative breast cancer

8 questions · 1 source

Clinical trials

Who was eligible for the KEYTRUDA KEYNOTE-522 trial?

What chemotherapy was given with KEYTRUDA in KEYNOTE-522?

Does the KEYTRUDA benefit come from treatment before or after surgery (KEYNOTE-522)?

What were baseline characteristics in the KEYTRUDA KEYNOTE-522 trial?

Study results

How often did KEYTRUDA plus chemotherapy leave no invasive cancer at surgery (KEYNOTE-522)?

What was KEYTRUDA event-free survival in KEYNOTE-522?

Does KEYTRUDA with chemotherapy lower the risk of death in early-stage TNBC (KEYNOTE-522)?

Interpreting study results

What are the limitations of KEYTRUDA KEYNOTE-522 survival subgroup results?